Molnupiravir is a ribonucleoside analogue and RNA polymerase inhibitor with broad-spectrum antiviral activity. Is the world's first oral anti-COVID-19 drug-19 for the treatment of adult mild to moderate coronavirus pneumonia.
Monavir is metabolized in vivo to produce β-D-N4- Hydroxycytidine (NHC), which is used as a substrate by virus RNA-dependent RNA polymerase (RdRp) to participate in the synthesis of novel coronavirus virus RNA.
By forming a stable base pair with G or A in the active center of RdRp, RNA products mutate, thus blocking the replication of novel coronavirus virus.
Monapivoxil is a prodrug of NHC. After metabolism, the ester bond is hydrolyzed, and the blood drug concentration can only be detected at 0.5- 1 hour after administration. The plasma concentration of NHC can be detected, and there is no accumulation between 1-5 days after administration. The recommended dosage is 800 mg (four 200 mg capsules), once every 12 hours, for 5 days.
As the first oral anti-COVID-19 drug in the world, the advent of Morupiravir provides a powerful means to prevent and treat COVID-19 for immunocompromised people who have not been vaccinated or have poor vaccination effect.